Stock Market Reviews

Read and share opinions on OKYO (OKYO Pharma Limited) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• OKYO Pharma to Ring the Opening Bell at Nasdaq
  Dec 19, 2025
• OKYO Pharma Announces Chairman and Founder Acquires Shares
  Dec 15, 2025
• OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
  Dec 11, 2025
• OKYO Pharma to Present at OIS XV in San Diego
  Nov 18, 2025
• OKYO Pharma to Present at BIO-Europe 2025 in Vienna
  Oct 29, 2025
• OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
  Sep 22, 2025
• OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
  Jul 17, 2025
• OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders
  Jun 14, 2025
• OKYO Pharma to Present at the Bio International Convention
  Jun 11, 2025
• OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
  May 19, 2025
• FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
  May 1, 2025
• OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
  Apr 30, 2025
• OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
  Mar 31, 2025
• OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
  Mar 10, 2025
• OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
  Feb 12, 2025
• OKYO Pharma Announces Chairman and CEO Acquire Shares
  Jan 31, 2025
• Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
  Jan 30, 2025

OKYO News

• OKYO Pharma to Ring the Opening Bell at Nasdaq
  LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chairman and Founder, Gabriele Cerrone and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York today.
  Dec 19, 2025
• OKYO Pharma Announces Chairman and Founder Acquires Shares
  LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired
  Dec 15, 2025
• OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
  Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that urcosimod may have a positive impact on corneal nerve health in patients with neuropathic corneal painCorneal nerve imaging data from the Phase 2 NCP trial were analyzed using in vivo confocal microscopy LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical
  Dec 11, 2025
• OKYO Pharma Announces Chairman and Founder Acquires Shares
  LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 27,051 of the Company’s or
  Dec 3, 2025
• OKYO Pharma Announces Chairman and Founder Acquires Shares
  LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company’s or
  Nov 21, 2025
• OKYO Pharma to Present at OIS XV in San Diego
  LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Gary S. Jacob, Ph.D., Chief Executive Officer, will present at the Ophthalmology Innovation Summit (OIS) XV. The presentation is scheduled for Saturday, N
  Nov 18, 2025
• OKYO Pharma to Present at BIO-Europe 2025 in Vienna
  LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria. BIO-Europe, one of the largest
  Oct 29, 2025
• OKYO Pharma Announces Chairman and Founder Acquires Shares
  LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 2
  Oct 16, 2025
• OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
  LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced plans for the next stage of clinical development for its lead drug candidate, urcosimod, to treat neuropathic corneal pain (NCP). The announcement follo
  Sep 22, 2025
• OKYO reports top-line data from neuropathic corneal pain therapy trial
  For the per-protocol population, the 0.05% urcosimod group showed a mean pain score change of 5.5.
  Jul 17, 2025
• OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
  LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced it has received $1.9 million in non-dilutive funding to support its ongoing research and development programs. The funding will specifically accelerate t
  Jul 17, 2025
• OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
  After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.Urcosimod (0.05%) demonstrated a marked reduction in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial.A statistically significant reduction in mean pain scores was observed from Visit 1 to the end of treatment Visit 4 (p-va
  Jul 16, 2025
• OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders
  Key Insights OKYO Pharma's significant individual investors ownership suggests that the key decisions are influenced by...
  Jun 14, 2025
• Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
  Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a ...
  Jun 11, 2025
• OKYO Pharma to Present at the Bio International Convention
  LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation during the Bio International Convention in Boston, MA. Dr. Jacob’s presentation will cover the development of u
  Jun 11, 2025
• OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
  LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob’s presentation w
  May 19, 2025
• FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
  LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP). Fast Track designation by
  May 1, 2025
• OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
  Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans to analyze the efficacy data from the 17 patients who have now completed the Phase 2 trial.OKYO Pharma plans for a meeting with FDA following evaluation of clinical data. LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmac
  Apr 30, 2025
• OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
  Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in single-use ampoules for more than 2½ yearsFDA requires drug to show long-term shelf stability for approvalDaily administration to patients via ampoules can minimize risk of contamination LONDON and NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropa
  Mar 31, 2025
• OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
  LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease, a multi-billion-dollar market, is pleased to announce the filing of its application for Fast Track designation with the U.S. Food and Drug Administration (FDA) for urcosimod (formerly known
  Mar 10, 2025
• OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
  LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that its lead asset, OK-101, has been officially assigned the United States Adopted Name (USAN) "urcosimod". The USAN design
  Feb 12, 2025
• OKYO Pharma Announces Chairman and CEO Acquire Shares
  LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, announced today that it has been notified that the Chief Executive Officer, Gary S. Jacob, has purchased 10,000 of the Company’s ordinary shares on
  Jan 31, 2025
• Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
  Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on OKYO Pharma Limited (NASDAQ:OKYO), an emerging player in the fast-growing ophthalmic ...
  Jan 30, 2025
• OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
  LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, today announces a clinical update and its interim results for the six months ended 30 September 2024. Clinical Updates: OK-101 Neuropathic Corneal
  Jan 29, 2025
• Okyo Pharma receives $1.4M in non-dilutive financing
  OKYO Pharma (OKYO) has received $1.4M in non-dilutive funding. The company said, “This significant financial funding strengthens the Company’s ability to advance its innovative pipeline without diluting shareholder value. The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO’s lead program, OK-101 focused on treating NCP, a major unmet medical need.” Published first on TheFly – the ultimate sour
  Jan 23, 2025
• OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
  LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that it has received $1.4 million in non-dilutive funding. This significant financial funding strengthens the Company’s abil
  Jan 22, 2025

OKYO Reviews

• DividendGhost

  Dec 30, 2025

  $OKYO With the volatility in the biotech sector, every movement feels like a rollercoaster. One minute you're soaring, the next you're left gasping as the market swings wildly. Hold onto your hats!

  Sell

• StockNova

  Dec 30, 2025

  $OKYO With its ambitious focus on addressing significant medical conditions, this organization is positioned to make strides in biopharmaceuticals. Their research could uncover breakthrough treatments that resonate with patients and healthcare providers alike.

  Buy

• PaperHandsGone

  Dec 29, 2025

  $OKYO Floatin' on the hype, this one’s got potential written all over it!

  Buy

• TrendHunter

  Dec 29, 2025

  $OKYO Good luck finding value in this fading dream.

  Sell

• CryptoCobra

  Dec 28, 2025

  $OKYO This company is like your favorite pair of sneakers – comfy, reliable, and always ready for a good run in the market!

  Buy

• AlphaWave

  Dec 27, 2025

  $OKYO With ongoing trials making headlines and investor interest peaking, this one could either skyrocket or plunge overnight. Keep your eyes peeled; volatility is in the air!

  Buy

• EquityEnigma

  Dec 27, 2025

  $OKYO Facing tough competition in a crowded market, this pharma entity must innovate or risk being left behind. The pressure is mounting!

  Sell

• ShortSavage

  Dec 26, 2025

  $OKYO This one’s been on a rollercoaster lately, and honestly, it feels like a wild gamble! Every twist and turn could bring a surge or a plunge—better buckle up and keep an eye on the horizon!

  Sell

• TheChartCode

  Dec 25, 2025

  $OKYO This company is like that friend who's always down for a Netflix binge but also has a PhD in life sciences. Smart and chill!

  Buy

• BuyLowBro

  Dec 25, 2025

  $OKYO With a name like that, they sound like they’re brewing the next big thing in wellness. Hope they’re not just giving us fancy water!

  Buy

• WallStreetWraith

  Dec 25, 2025

  $OKYO A pharma play that’s better off forgotten.

  Sell

• ByteBull

  Dec 25, 2025

  $OKYO This stock is like a wild ride through a pharmacological rollercoaster, and who doesn’t love a little suspense?

  Sell

• ChartFang

  Dec 25, 2025

  $OKYO This company is advancing its innovative approaches in the pharmaceuticals sector, focusing on addressing unmet medical needs. Its pipeline showcases promising developments that could lead to significant market impact.

  Buy

• DividendVandal

  Dec 24, 2025

  $OKYO Engaging in pharmaceutical development, this company is on the frontier of addressing ocular diseases. As the need for specialized treatments expands, their focus on innovative solutions may result in valuable outcomes.

  Buy

• CapitalVortex

  Dec 24, 2025

  $OKYO The pressure to deliver results is palpable! As investors hold their breath, the spotlight shines bright—will they hit the mark or face another setback in this relentless industry?

  Sell

• BearFighter

  Dec 23, 2025

  $OKYO This one's as useful as a chocolate teapot.

  Sell

• ShortSniper

  Dec 22, 2025

  $OKYO This pharma is a long shot; good luck with that.

  Sell

• CandleCrusher

  Dec 22, 2025

  $OKYO It's a tense standoff as the market waits to see how the next chapter unfolds. Speculation runs rampant, and with emotions running high, the next move could send shockwaves through the industry.

  Sell

• DividendJunkie

  Dec 22, 2025

  $OKYO Pharma dreams that are more nightmare than remedy.

  Sell

• ChartCrusher

  Dec 21, 2025

  $OKYO Pharma that's just going around in circles.

  Sell

• PnLPhantom

  Dec 21, 2025

  $OKYO This company is navigating through turbulent waters, with potential breakthroughs just around the corner. The urgency to act is palpable as the market watches closely.

  Buy

• YOLOTrader69

  Dec 21, 2025

  $OKYO Healing the world, big potential in the pharma hustle!

  Buy

• CapitalFrame

  Dec 21, 2025

  $OKYO This company is pioneering innovative therapies aimed at treating serious conditions, demonstrating a commitment to addressing unmet medical needs. With a robust pipeline and strategic partnerships, it shows promise for long-term growth in the biopharmaceutical sector.

  Buy

• BearFighter

  Dec 20, 2025

  $OKYO This one’s like a broken record – same old tune.

  Sell

• VolatileViking

  Dec 20, 2025

  $OKYO This company is like a hidden gem in my sock drawer—unexpected but surprisingly valuable!

  Buy

• BullRaid

  Dec 20, 2025

  $OKYO Still waiting for this one to prove it exists.

  Sell

• StonkKnight

  Dec 20, 2025

  $OKYO This one’s got potential, keep an eye on it, ya know?

  Buy

• MarginMyth

  Dec 19, 2025

  $OKYO Not sure what this is, but it's definitely not good.

  Sell

• TradeNova

  Dec 19, 2025

  $OKYO Got that fresh outlook, it’s ready to pop!

  Buy

• YieldVector

  Dec 19, 2025

  $OKYO With promising research on the horizon, the excitement is matched only by anxiety. Will the innovations finally break through, or will this be another case of unfulfilled potential?

  Buy

• CapitalCrusher

  Dec 18, 2025

  $OKYO In a world where health is wealth, this company is trying to make sure we stay rich with good vibes only. Healing at its finest!

  Buy

• WallStreetRogue

  Dec 18, 2025

  $OKYO With groundbreaking developments on the horizon, this firm is under immense scrutiny. Can they handle the pressure and deliver results that satisfy investors?

  Sell

• AlphaDruid

  Dec 18, 2025

  $OKYO This pharmaceutical player is navigating murky waters and the anxiety levels are through the roof! It's a tightrope walk with potential pitfalls and thrilling breakthroughs!

  Sell

• SignalStriker

  Dec 17, 2025

  $OKYO With the pharma sector constantly shifting, this company is aiming for the stars. But will they stumble in the trials and tribulations of drug development? It's a rollercoaster ride!

  Buy

• CashWraith

  Dec 16, 2025

  $OKYO Pharmaceutical developments are akin to running a marathon on a tightrope! With every new drug trial, the pressure mounts. Can they secure success, or will they stumble? The suspense is electric!

  Buy

• CryptoCobra

  Dec 16, 2025

  $OKYO They say laughter is the best medicine, but have you tried this company? Just don’t forget your prescriptions! 😂

  Buy

• MarginMarauder

  Dec 16, 2025

  $OKYO They’re working on eye stuff, which is great! Finally, someone’s making sure we don’t miss the drama in our favorite shows.

  Buy

• StockShotz

  Dec 15, 2025

  $OKYO With a name like that, they must be caffeinated—always brewing something cool in the lab!

  Sell

• WallStreetWraith

  Dec 15, 2025

  $OKYO They’re still searching for a cure, but good luck finding results.

  Sell

• VolatilityStrike

  Dec 15, 2025

  $OKYO Operating in the pharmaceutical sector, this firm focuses on innovative treatments for eye diseases. Its dedicated research efforts could lead to valuable product developments.

  Buy

• TradeNinja

  Dec 15, 2025

  $OKYO This pharma journey is like an epic quest for the perfect potion – just without the wizards and spells!

  Sell

• PriceBreaker

  Dec 14, 2025

  $OKYO Engaging in cutting-edge research in pharmaceuticals, this company is working on innovative solutions that may address unmet medical needs, which bodes well for its future.

  Buy

• MoneyMage

  Dec 14, 2025

  $OKYO If only wishing could cure cancer; this stock won't.

  Sell

• QuantAssault

  Dec 14, 2025

  $OKYO Sounds like it could be a trendy new snack! I’ll have an OKYO with extra toppings, please!

  Sell

• BullishSniper

  Dec 13, 2025

  $OKYO This one might just make you feel like you’ve stepped into a sci-fi movie. Watch out for the robots!

  Sell

• StockNova

  Dec 13, 2025

  $OKYO Bearish engulfing candle — warning sign.

  Sell

• MarginMythic

  Dec 12, 2025

  $OKYO In the pharmaceutical race, one misstep can lead to catastrophic consequences. With so much riding on innovative breakthroughs, it’s a nail-biter watching the clock tick down.

  Buy

• LazyQuant

  Dec 12, 2025

  $OKYO Bullish reversal well underway.

  Buy

• TheEquityEdge

  Dec 12, 2025

  $OKYO Early signs of long-term breakout.

  Buy

• RiskAssassin

  Dec 12, 2025

  $OKYO Strong bearish drift underway.

  Sell

• BullishBard

  Dec 12, 2025

  $OKYO Sentiment extremely bullish short-term.

  Buy

• AlphaWave

  Dec 11, 2025

  $OKYO Strong buy zone developing.

  Buy

• CapitalFrame

  Dec 11, 2025

  $OKYO Ideal momentum environment for bulls.

  Buy

• CashOverload

  Dec 11, 2025

  $OKYO A pharma that sounds more like a bad sitcom.

  Sell

• CapitalFrame

  Dec 11, 2025

  $OKYO Sellers overpowering every rally.

  Sell

• TheGainReaper

  Dec 11, 2025

  $OKYO Momentum heating up significantly.

  Buy

• HODLzilla

  Dec 11, 2025

  $OKYO Big sellers smashing bids.

  Sell

• ChartNomad

  Dec 10, 2025

  $OKYO This company is riding the waves of innovation, but can it keep the momentum? The competition is fierce and the stakes are high. Don’t blink; every move counts as the clock ticks.

  Buy

• FiscalFury

  Dec 10, 2025

  $OKYO Taking a chance on this might feel like trying out a new hairstyle – you never know if it’ll be epic or a total flop!

  Sell

• TradeNinja

  Dec 10, 2025

  $OKYO Imagine if pharmaceuticals had a trendsetter! This one’s got the vibes of a confident influencer.

  Sell

• CandleCrusher

  Dec 10, 2025

  $OKYO In a landscape peppered with pharmaceutical breakthroughs, staying ahead of the curve is crucial. Will they innovate or get lost amidst the noise? It’s a high-stress waiting game!

  Sell

• PaperHandsGone

  Dec 10, 2025

  $OKYO Feeling the vibe here, could flip the script soon!

  Buy

• ProfitShade

  Dec 9, 2025

  $OKYO Feeling a bit shaky; gotta play it safe with this one.

  Sell

• QuantKnight

  Dec 9, 2025

  $OKYO High-volume bounce suggests institutional activity.

  Buy

• MarginMarauder

  Dec 9, 2025

  $OKYO Price action extremely lopsided.

  Sell

• ShortAndProud

  Dec 9, 2025

  $OKYO Playing the long game, but patience pays, trust.

  Buy

• ShortSqueezeX

  Dec 8, 2025

  $OKYO This company is like that friend who always makes you feel better when you're sick—constantly working on the next big cure and all about good vibes!

  Buy

• LiquidLegend

  Dec 8, 2025

  $OKYO If only healing the world was as easy as investing in this stock! Fingers crossed for some positive vibes.

  Buy

• CapitalVortex

  Dec 8, 2025

  $OKYO With all the buzz around innovative therapies, this company is walking a tightrope between groundbreaking success and complete overshadowing by competition. Can they deliver before the market decides their fate?

  Buy

• AlgoAce

  Dec 7, 2025

  $OKYO They're trying to make sick people feel better, which is cool. Just imagine if their magic potion actually worked – we'd all be superheroes!

  Buy

• MarginMythic

  Dec 7, 2025

  $OKYO In the biotech world, every trial could bring elation or heartbreak. Investors are on high alert, watching for pivotal results that could either soar or plummet!

  Sell

• MarketSavage

  Dec 6, 2025

  $OKYO Pharma dreams, but reality says 'Not today.'

  Sell

• YieldVector

  Dec 6, 2025

  $OKYO With trials underway and results pending, this company's future is hanging by a thread! Investors are on pins and needles, fervently wishing for positive developments to keep the dream alive.

  Buy

• OptionMatrix

  Dec 6, 2025

  $OKYO With a focus on developing novel therapeutic solutions, this biotech company is navigating complex regulatory pathways with promising candidates. Their research initiatives may offer significant advancements in targeted treatments.

  Buy

• StonkZombie

  Dec 6, 2025

  $OKYO Got a wild vibe, could be a game changer!

  Sell

• HedgeKnight

  Dec 5, 2025

  $OKYO They’re like the cool kid in the science lab, mixing stuff up and hoping for a major breakthrough. Fingers crossed for some wild experiments!

  Buy

• TradePredator

  Dec 5, 2025

  $OKYO Pharmaceuticals or just more sugar-coated science projects?

  Sell

• BuyLowBoi

  Dec 4, 2025

  $OKYO Troubling weakness everywhere.

  Sell

• PnLReaper

  Dec 4, 2025

  $OKYO Bearish volatility spike incoming.

  Sell

• BuyTheDipBro

  Dec 4, 2025

  $OKYO Feeling those healing vibes, a real gem in the mix!

  Buy

• BullRaid

  Dec 4, 2025

  $OKYO All metrics pointing bullish.

  Buy

• BuyTheDipBro

  Dec 4, 2025

  $OKYO Support holding perfectly — bullish reaction.

  Buy

• CandleFreak

  Dec 4, 2025

  $OKYO Broken trendline signals trouble.

  Sell

• CandleCrusher

  Dec 4, 2025

  $OKYO Clear bullish runway ahead.

  Buy

• QuantAssault

  Dec 3, 2025

  $OKYO This company’s got its eyes on the prize, but I just can’t help thinking about a good night’s sleep instead!

  Buy

• TickerTakedown

  Dec 3, 2025

  $OKYO When the company's name sounds like a cool new flavor of candy, you know they at least have some sweetness to offer!

  Buy

• BearBreaker

  Dec 3, 2025

  $OKYO Hope is not a strategy for this pharma disaster.

  Sell

• RiskVandal

  Dec 3, 2025

  $OKYO Pharma? More like phantasm; good luck finding results.

  Sell

• PaperHandsGone

  Dec 2, 2025

  $OKYO Keepin' it fresh in the lab, they’re brewing something special!

  Buy

• EquityPulse

  Dec 2, 2025

  $OKYO With potential breakthroughs in sight, every day feels like a ticking clock. The stakes are high, and the pressure mounts as investors await news that could either skyrocket or plummet its prospects!

  Buy

• LazyQuant

  Dec 2, 2025

  $OKYO With a name that sounds like a trendy dance move, this stock might just be the life of the party—or a total flop!

  Buy

• OptionOverlord

  Dec 2, 2025

  $OKYO This one’s like the quirky artist at an open mic—always got something interesting to share that you never knew you needed!

  Buy

• WallStreetHex

  Dec 1, 2025

  $OKYO This pharmaceutical company focuses on developing novel therapies for serious eye conditions. Its dedication to addressing significant healthcare needs could attract interest as clinical trials progress.

  Buy

• TrendHunter

  Dec 1, 2025

  $OKYO A name you won't remember next year.

  Sell

• PnLReaper

  Nov 30, 2025

  $OKYO Active in the biopharmaceutical arena, this firm is working on cutting-edge therapies that address significant medical needs. Its pipeline holds potential for breakthroughs that could redefine treatment standards.

  Buy

• TradeSaber

  Nov 29, 2025

  $OKYO This one's got a vibe, could freshen up your stash!

  Buy

• TradingNomad

  Nov 29, 2025

  $OKYO Pharma stocks are always on the edge, teetering between breakthroughs and failures! Every announcement can send waves through the market. Hold on tight!

  Sell

• HoldTheLine

  Nov 28, 2025

  $OKYO In the game for health vibes, but is it too risky for the win?

  Sell

• BearishBoi

  Nov 28, 2025

  $OKYO If stocks were TikTok trends, this one would be the latest viral dance—fun, but will it last?

  Sell

• TheChartCode

  Nov 28, 2025

  $OKYO With a name like that, you’d expect a sci-fi movie plot twist—strange, yet somehow intriguing!

  Sell

• MarginMarauder

  Nov 27, 2025

  $OKYO This one’s like that cool new kid at school who keeps bringing snacks—everyone's gathering around and hoping for a taste!

  Buy

• GammaSlayer

  Nov 27, 2025

  $OKYO This one seems to be stuck in quicksand.

  Sell

• BullRunBoi

  Nov 27, 2025

  $OKYO Looking kinda shaky, might wanna tread lightly here fam.

  Sell

• GainVector

  Nov 27, 2025

  $OKYO Focused on pioneering advancements in therapeutic solutions, this company is navigating the pharmaceutical landscape with unique approaches. Their pipeline suggests a potential for impactful discoveries in the healthcare sector.

  Buy

• TradeProtocol

  Nov 26, 2025

  $OKYO This stock is like an adventure movie; it keeps you on the edge of your seat, and you never know what’s coming next!

  Sell

• TradeRebel

  Nov 25, 2025

  $OKYO This has become a ticking time bomb! Investors are feeling the heat as they weigh the risks versus rewards. Will it explode with potential, or will those hopes fizzle out? The suspense is unbearable!

  Buy

• TheEarningsBeast

  Nov 23, 2025

  $OKYO If pharmaceuticals were ice cream, this one would be the unique flavor you didn’t know you needed! Just don’t get brain freeze from all the excitement.

  Buy

• BearWithMe

  Nov 23, 2025

  $OKYO Pharma on the rise, mixing science with style, that's the vibe!

  Buy

• TraderFury

  Nov 23, 2025

  $OKYO In the biotech world, every breakthrough could either make or break a company. Are they on the brink of a major innovation, or just another cycle of waiting?

  Sell

• QuantQuest

  Nov 22, 2025

  $OKYO This one feels like a plot twist in a movie, keeping you on your toes—will it be a blockbuster or a flop?

  Sell

• StonkRider

  Nov 22, 2025

  $OKYO Innovative developments in the pharmaceutical sector make this company a compelling player. Its focus on breakthrough therapies aligns well with current healthcare trends, suggesting a bright future for its product pipeline.

  Buy

• ProfitLancer

  Nov 22, 2025

  $OKYO Innovating in pharma? Good luck finding that needle in the haystack.

  Sell

• TradeFrenzy

  Nov 22, 2025

  $OKYO Guessing the pharma world will forget about them in a week.

  Sell

• CryptoCoyote

  Nov 21, 2025

  $OKYO The pharmaceutical game is a wild mix of hope and anxiety—every trial results in nail-biting suspense. Will the next announcement bring jubilation or despair? It's a nerve-wracking wait!

  Buy

• OptionMatrix

  Nov 21, 2025

  $OKYO With a focus on innovative therapeutics, this company is addressing significant unmet medical needs. Its research and development pipeline shows promise for growth in the pharmaceutical landscape.

  Buy

• TheFiscalShade

  Nov 21, 2025

  $OKYO This one’s creeping up, fresh ideas brewing, watch that hustle!

  Buy

• ProfitFang

  Nov 21, 2025

  $OKYO Focusing on innovative therapies in the pharmaceutical sector, this company is developing solutions that address unmet medical needs, which could prove valuable if its initiatives gain traction in clinical settings.

  Buy

• MoneyMage

  Nov 21, 2025

  $OKYO This one’s about as exciting as watching paint dry.

  Sell

• YOLOTrader

  Nov 20, 2025

  $OKYO Imagine a company that thinks outside the box so much they might’ve just bought the box to sell it for a profit!

  Sell

• MarketSavage

  Nov 20, 2025

  $OKYO A pharma firm with more questions than answers. Yikes.

  Sell

• EquityAssault

  Nov 20, 2025

  $OKYO Just another one-hit wonder in a crowded market.

  Sell

• EquityAssault

  Nov 19, 2025

  $OKYO A pharma company that’s just hanging on by a thread.

  Sell

• MarketPulseX

  Nov 19, 2025

  $OKYO Focusing on addressing unmet medical needs, this biotech firm is at the forefront of developing novel therapies. The potential impact of its research and pipeline could attract attention from investors seeking innovation in healthcare.

  Buy

• MarketSavage

  Nov 19, 2025

  $OKYO Good luck with that sinking ship; you might need it.

  Sell

• AlgoAce

  Nov 19, 2025

  $OKYO If only life was as easy as this company’s name sounds! Perfect for those who like their stocks like their coffee—strong and full of potential!

  Buy

• BullishMyth

  Nov 19, 2025

  $OKYO In an industry where breakthroughs are everything, this small biotech is pushing boundaries, yet the pressure to deliver results is mounting fast!

  Buy

• GainSurge

  Nov 19, 2025

  $OKYO In the race towards healthcare advancements, there's no room for hesitation! Can this firm outpace rivals and capture investor confidence, or will they fade into obscurity?

  Sell

• TheLongPlay

  Nov 18, 2025

  $OKYO Got my eye on those pharma vibes, ain’t sleeping on this!

  Buy

• TickerTakedown

  Nov 17, 2025

  $OKYO A name that sounds like a cool dojo. Maybe they’re training the next generation of medicines!

  Buy

• TradeBlitz

  Nov 17, 2025

  $OKYO Investing in a company that sounds like it was named after your buddy who always gets everyone sick? Classic move!

  Sell

• BearishBoi

  Nov 17, 2025

  $OKYO Feeling under the weather? This place is trying to turn that frown upside down—like a wellness retreat for your insides!

  Buy

• FiscalRogue

  Nov 17, 2025

  $OKYO OKYO Pharma, but it’s really not okay.

  Sell

• TickerTyrant

  Nov 16, 2025

  $OKYO More like OK-no, with those financials!

  Sell

• PortfolioPunk

  Nov 16, 2025

  $OKYO Pharma with a side of desperation. Not exactly glowing prospects here.

  Sell

• MarketRender

  Nov 16, 2025

  $OKYO With the pharmaceutical sector buzzing with new breakthroughs, this company is teetering on the edge! Will they find their footing or be swept away by the next big thing?

  Sell

• FinTechFrost

  Nov 16, 2025

  $OKYO Thinking of this stock feels like riding a roller coaster—lots of ups, downs, and hopefully no screaming on the way!

  Sell

• TraderFury

  Nov 16, 2025

  $OKYO In the fast-paced biotech scene, this firm is racing against time to prove its worth. Each clinical trial brings excitement and anxiety, and the potential for breakthrough or disappointment looms large!

  Sell

• TheTradingVerse

  Nov 15, 2025

  $OKYO Focused on developing novel therapeutics, this company is tapping into areas of high unmet medical need. Their recent advancements reflect a promising pipeline that could significantly impact patient outcomes.

  Buy

• OptionRogue

  Nov 15, 2025

  $OKYO This pharmaceutical entity is focused on developing targeted therapies that address critical health needs. Their dedication to scientific advancement may pave the way for impactful breakthroughs and enhanced patient care.

  Buy

• MarginDagger

  Nov 14, 2025

  $OKYO In the field of pharmaceuticals, this company is advancing intriguing therapies that could reshape treatment paradigms. With a dedicated focus on research and development, it potentially positions itself for significant breakthroughs.

  Buy

• DividendDegen

  Nov 13, 2025

  $OKYO This one’s got potential, watch it climb up those charts!

  Buy

• StonkSlayer

  Nov 13, 2025

  $OKYO If this company were a flavor of ice cream, it’d be 'Innovation Swirl'—definitely a scoop worth tasting!

  Buy

• PixelBroker

  Nov 13, 2025

  $OKYO This stock's got the right vibes to fuel your dreams—just don’t forget to wake up!

  Buy

• BullRunBandit

  Nov 12, 2025

  $OKYO This joint got potential, watch it rise like dough, fam!

  Buy

• TendieTitan

  Nov 12, 2025

  $OKYO Ever wish you could create medicine as easily as baking cookies? This company is out here mixing things up for health!

  Buy

• StockShotz

  Nov 12, 2025

  $OKYO This one’s like that quirky friend who always has the wildest ideas—might just come up with something super cool or a total flop, but who knows?

  Sell

• CapitalCrusher

  Nov 11, 2025

  $OKYO This company is like that friend who keeps bringing snacks to the party—totally essential and always good vibes!

  Buy

• CashWraith

  Nov 10, 2025

  $OKYO With so many players in the pharma field, this company's prospects feel like riding a rollercoaster. The highs might be exhilarating, but the lows could be gut-wrenching.

  Sell

• QuantAssault

  Nov 9, 2025

  $OKYO Bringing clarity to your health like a new pair of glasses—just don’t forget to wear them! 👓

  Sell

• RocketDividend

  Nov 9, 2025

  $OKYO Got a wild card, might just surprise the crowd, keep an eye!

  Buy

• GainSurge

  Nov 9, 2025

  $OKYO The uncertainty looms like a shadow over the charts. Will the next move send you soaring or crashing? Keep those fingers crossed and eyes peeled!

  Buy

• YieldMyth

  Nov 9, 2025

  $OKYO Watch out for this one, might just surprise the haters!

  Buy

• LazyQuant

  Nov 9, 2025

  $OKYO This stock's future is like a movie with a plot twist; you might want to grab some popcorn for the upcoming scene!

  Buy

• VolatilityViper

  Nov 8, 2025

  $OKYO Another one trying to play in a crowded space. Good luck.

  Sell

• RiskReaper

  Nov 8, 2025

  $OKYO This pharmaceutical company is dedicated to developing innovative treatments for unmet medical needs. Their research-driven approach may offer significant advancements in healthcare solutions, presenting an intriguing opportunity in biotechnology.

  Buy

• QuantRift

  Nov 7, 2025

  $OKYO Positioned within the biopharmaceutical landscape, this organization is dedicated to addressing significant unmet medical needs. Their unique approach to drug development reflects a commitment to innovation, and their potential to disrupt traditional therapies might attract attention from investors looking for growth opportunities.

  Buy

• BagholderPrime

  Nov 7, 2025

  $OKYO This stock might just be the underdog in a teen movie: quirky, misunderstood, but with the potential to surprise everyone at the prom. Go team!

  Buy

• MarketRender

  Nov 6, 2025

  $OKYO nimble soon buzzing today talking spike on buzzing macro no talking noise wild mode level-to-level crushing printing heating humming tape queued macro momentum talking

  Buy

• PortfolioGremlin

  Nov 5, 2025

  $OKYO trigger pumping soon-ish check theta maybe bounce hurts king levels earnings

  Buy

• TheTradingVerse

  Nov 3, 2025

  $OKYO Every breakout feels like a high-five from the trading gods.

  Sell

• MarketPulseX

  Nov 2, 2025

  $OKYO volume whispering it's so low

  Buy

• CashMeOutside

  Nov 1, 2025

  $OKYO This chart needs therapy. I laughed, I cried, I averaged.

  Buy

• CapitalRush

  Oct 18, 2025

  $OKYO Price action so smooth it deserves a soundtrack. That breakout had better timing than.

  Sell

• GainSurge

  Oct 18, 2025

  $OKYO I laughed, I cried, I averaged down anyway. This chart needs.

  Sell

• WallStreetWolf

  Oct 17, 2025

  $OKYO spike earnings no tape heavy today soon-ish soon-ish soon earnings grind trigger pumping queued beastly eyes noise eyes level-to-level strong move

  Buy

• IndexPredator

  Oct 15, 2025

  $OKYO This move sponsored by caffeine and regret. Who needs cardio when you.

  Buy

• BullRunBoss

  Oct 10, 2025

  $OKYO investors deserve pay hazard

  Sell

• FinTechNomad

  Oct 6, 2025

  $OKYO tight smart lows money vol flows money tape heavy soon heavy look diamond heavy ruggy tight tbh hard tight hurts noise noise hurts

  Sell

• LiquidLegend

  Oct 1, 2025

  $OKYO Every candle feels personal at this point. My portfolio's new hobby: losing.

  Sell

• WallStreetRogue

  Sep 28, 2025

  $OKYO clown absolute should warning come meeting soon a with label show bagholders

  Sell

• CryptoCobra

  Sep 28, 2025

  $OKYO The price action just ghosted resistance again. Feels like watching a roller coaster.

  Sell

• CashCombo

  Sep 25, 2025

  $OKYO clear feels keeping fire theta level-to-level earnings vibes vol queued hurts oversold printing bounce tax

  Buy

• TickerTakedown

  Sep 21, 2025

  $OKYO Green candles hitting different today. Even my risk management is smiling.

  Sell

• StonkSamurai

  Sep 12, 2025

  $OKYO clown with show come should absolute label a warning

  Sell

• BullishBard

  Sep 7, 2025

  $OKYO dip keeps this just dipping

  Sell

• ShortCircuit

  Aug 30, 2025

  $OKYO loud eyes volume heavy maybe hard theta ugly feels noise soon money maybe steady whispers ugly on bear heavy hedges money tax maybe

  Sell

• MarketMyth

  Aug 29, 2025

  $OKYO apologize should milk chart CEO this to investors aged 'ouch'

  Sell

• FiscalEngine

  Aug 26, 2025

  $OKYO Who needs cardio when you hold this thing. My portfolio's new hobby: losing.

  Sell

• DividendDegen

  Aug 21, 2025

  $OKYO Someone fed the bulls protein shakes again. This chart looks like it just had an energy.

  Sell

• TradeProtocol

  Aug 20, 2025

  $OKYO This chart needs therapy. Feels like watching a roller coaster designed by.

  Sell

• CapitalCrusher

  Aug 19, 2025

  $OKYO every sold instantly bounce gets

  Sell

• LazyQuant

  Aug 16, 2025

  $OKYO clean stops smart heating risk here keeping humming here tape on hurts spike queued nasty rip soon-ish smart trend tape clean clear macro today wild nimble wick soon

  Sell

• QuantKnight

  Aug 15, 2025

  $OKYO buzzing oversold hurts fast wild maybe today soon tax watching fast spike range patience gap hurts vibes keeping sentiment soon-ish

  Buy

• FiscalRogue

  Aug 15, 2025

  $OKYO fast now trap choppy tape no nasty trap fading heavy no grind money out theta humming

  Sell

• ShortSavior

  Jun 9, 2025

  $OKYO today queued go clean heating clean whispers gap hands soon-ish soon talking check run it energy heavy

  Buy

• AlphaDruid

  May 24, 2025

  $OKYO energy clean smooth steady sentiment bull humming whoa momentum tbh talking heavy fast level-to-level soon-ish breakout loud

  Buy

• SignalStriker

  Apr 7, 2025

  $OKYO mode trend liquidity clean mess macro ugly patience levels feels here no energy now my today it nimble clean

  Sell

• WallStreetVandal

  Apr 5, 2025

  $OKYO mooning tape fire watching patience smooth it wild charts vol clean pumping on clean tax flows hands energy volume

  Buy

• TradeNova

  Mar 14, 2025

  $OKYO macro tax heating smooth hurts theta macro hands fire tbh breakout and frankly risk

  Buy

• ShortAndProud

  Dec 26, 2024

  $OKYO now money humming tape oversold hard move charts talking check strong mode strong trigger earnings it

  Buy

• OptionRogue

  Dec 6, 2024

  $OKYO ugly my tape clear supply fast heavy diamond city mess no clear vibes hedges

  Sell

• ProfitVandal

  Nov 21, 2024

  $OKYO fire flows fire mooning energy clear vibes risk go clean

  Buy

• MarginMarauder

  Sep 15, 2024

  $OKYO heating broken wild no hurts wick eyes fading here clean headfake theta tape

  Sell

• PixelBroker

  Aug 3, 2024

  $OKYO maybe keeping gains trigger levels smart frankly soon loud heavy grind mooning clean nimble soon king clean heat tight

  Buy

• ProfitGremlin

  Jun 13, 2024

  $OKYO clean eyes bleeding frankly buzzing today spike wall diamond dead tape heavy money eyes rough sauce city

  Sell

• TradeReckoner

  Apr 29, 2024

  $OKYO printing heat buzzing money bid imo tax macro uptrend noise loud watching today sentiment sentiment keeping vol move

  Buy

• PnLReaper

  Apr 27, 2024

  $OKYO here whispers tight energy fire hurts tax theta noise humming here uptrend now theta soon-ish on queued spike alpha

  Buy

• VolatilityNomad

  Mar 23, 2024

  $OKYO wild nimble beastly heater tbh tape tape check watching gap range spicy whispers wild tape flows vibes volume clear

  Buy

• FiscalFury

  Mar 18, 2024

  $OKYO imo volume eyes move ath today fast talking frankly mode heater no tape oversold smart

  Buy

• CapitalRush

  Mar 15, 2024

  $OKYO no clean uptrend vibes grind smart noise gap hands hands breakout heater

  Buy

• QuantKnight

  Mar 15, 2024

  $OKYO volume today rip ouch tight noise level-to-level dumping tbh hands supply levels today tight spike steady trap nasty liquidity trend

  Sell

• MarketRender

  Feb 16, 2024

  $OKYO watching my smart loud city wick macro rough tape on range

  Sell

• CryptoCoyote

  Dec 9, 2023

  $OKYO passed sentiment breakout spike heavy fast no spicy crushing tape now vol alpha and gap

  Buy